Uncover key drivers, emerging technologies, and competitive movements shaping the advanced therapy medicinal products market from 2026–2035 with trusted insights from The Business Research Company
How is the Advanced Therapy Medicinal Products Market size predicted to change over the forecast window of 2026–2035?
The advanced therapy medicinal products market has experienced significant expansion in recent times. Projections indicate an increase from $51.34 billion in 2025 to $61.41 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 19.6%. Historically, this market’s expansion was influenced by several factors, including the scarcity of advanced therapy products, a dependency on conventional biologics, undeveloped regulatory frameworks, the substantial expense associated with gene and cell therapies, and restricted distribution networks.
The advanced therapy medicinal products market size is projected to experience swift expansion in the coming years. This market is set to reach $124.43 billion by 2030, driven by a compound annual growth rate (CAGR) of 19.3%. Factors contributing to this growth during the forecast period include technological progress in gene editing and stem cell therapies, increased investment in personalized medicine, a higher incidence of rare and chronic diseases, the broadening of hospital pharmacy and specialty clinic networks, and the incorporation of AI-driven manufacturing and automation. Key trends anticipated for the forecast period encompass a surge in the adoption of autologous and allogeneic therapies, the widening scope of gene editing and viral vector technologies, a heightened emphasis on treatments for rare diseases, the integration of automation into therapy manufacturing, and an increase in collaborations between hospitals and specialty clinics.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25689&type=smp
Which Drivers Are Contributing To The Expansion Of The Advanced Therapy Medicinal Products Market?
The advanced therapy medicinal products market is anticipated to expand due to the escalating demand for personalized medicine. Personalized medicine represents a medical approach that customizes treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. This increasing demand for personalized medicine primarily arises from the growing prevalence of chronic diseases, as it enables tailored treatments that improve patient outcomes and reduce side effects. Advanced therapy medicinal products facilitate personalized medicine by providing bespoke treatments, such as gene, cell, and tissue-engineered therapies, that target the unique genetic and biological profiles of individual patients. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. The 2023 approvals also included seven cancer drugs and three for other diseases and conditions. Therefore, the rising demand for personalized medicine is a significant driver for the growth of the advanced therapy medicinal products market.
What Segment Classifications Make Up The Advanced Therapy Medicinal Products Market?
The advanced therapy medicinal products market covered in this report is segmented –
1) By Product: Somatic Cell Therapy Medicinal Products, Tissue Engineered Medicinal Products, Gene Therapy Medicinal Products
2) By Technology: Gene Editing Technologies, Viral Vector Technology, Stem Cell Technology, Automation And Artificial Intelligence-Driven Processes
3) By Application: Muscular Dystrophies, Alzheimer’s, Hemophilia, Cystic Fibrosis, Other Applications
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Somatic Cell Therapy Medicinal Products: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, Dendritic Cell Therapy, Natural Killer Cell Therapy
2) By Tissue Engineered Medicinal Products: Autologous Tissue-Engineered Products, Allogeneic Tissue-Engineered Products, Scaffold-Based Tissue Engineering, Scaffold-Free Tissue Engineering, Skin Substitutes
3) By Gene Therapy Medicinal Products: In Vivo Gene Therapy, Ex Vivo Gene Therapy, Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Gene Editing Therapies
What Trends Are Driving The Growth Trajectory Of The Advanced Therapy Medicinal Products Market?
Leading companies in the advanced therapy medicinal products (ATMP) market are concentrating on developing groundbreaking treatments, such as gene editing cell therapies, to provide targeted and potentially curative solutions for conditions like ß thalassemia and sickle cell disease. These gene editing cell therapies involve collecting a patient’s hematopoietic stem cells and precisely modifying their genome externally, often utilizing CRISPR Cas9 to correct harmful mutations or activate beneficial genetic pathways, thereby offering a personalized alternative to traditional allogeneic bone marrow transplantation, which relies on donor matching and carries risks such as graft versus host disease. For instance, in January 2024, Vertex Pharmaceuticals, a US-based biotechnology company, obtained US Food and Drug Administration (FDA) approval for CASGEVY (exagamglogene autotemcel, or exa cel), a CRISPR Cas9-based gene editing cell therapy designed for transfusion-dependent ß thalassemia. The therapy uses autologous CD34+ stem and progenitor cells, edits the erythroid-specific BCL11A enhancer to elevate fetal hemoglobin levels, and has demonstrated sustained clinical improvements, with the potential to achieve transfusion independence for many patients and significantly reduce or eliminate the need for regular blood transfusions.
Which Leading Companies Dominate The Advanced Therapy Medicinal Products Market Share?
Major companies operating in the advanced therapy medicinal products market are F. Hoffmann-La Roche Limited., Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited., Lonza Group AG, Catalent Inc., BioMarin Pharmaceutical Inc., AGC Biologics Inc., ViaCyte Inc., Rentschler Biopharma SE, JCR Pharmaceuticals Co. Ltd., Vericel Corporation, UniQure N.V., Fate Therapeutics Inc., WuXi Advanced Therapies Inc., Celonic Group AG, Pharmicell Co. Ltd., Magenta Therapeutics Inc, MEDIPOST Co. Ltd., Kolon TissueGene Inc
Access The Complete Report For Deeper Market Insights:
How Does The Advanced Therapy Medicinal Products Market Perform Across Major Global Regions?
North America was the largest region in the advanced therapy medicinal products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Advanced Therapy Medicinal Products Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25689&type=smp
Browse Through More Reports Similar to the Global Advanced Therapy Medicinal Products Market 2026, By The Business Research Company
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Market Report 2026
Herbal Medicine Market Report 2026
https://www.thebusinessresearchcompany.com/report/herbal-medicine-global-market-report
Anti Inflammatory Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model